Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

@article{Smith2003RandomizedCT,
  title={Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.},
  author={Matthew Raymond Smith and James Eastham and Donald M Gleason and Daniel Shasha and Simon Tchekmedyian and Norman R. Zinner},
  journal={The Journal of urology},
  year={2003},
  volume={169 6},
  pages={2008-12}
}
PURPOSE A multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer. MATERIALS AND METHODS Men with M0 (no distant metastases) prostate cancer beginning androgen deprivation therapy were randomly assigned to receive 4 mg. zoledronic acid or placebo intravenously every 3 months for 1 year. The primary… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
172 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 172 extracted citations

Similar Papers

Loading similar papers…